RBM-007

N/A

Report date: 2023/12/13 10:25:23
NME

Base Information

Drug NameRBM-007
Drug Alias NameUmedaptanib pegolRBM-007ID3 (21)APT-F2
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionFibroblast growth factor 2 inhibitors
TargetsFibroblast growth factor 2
Therapy Area/IndicationsMacular DegenerationAchondroplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRibomic
China Registration ClassN/A

Develop Information

Active CompaniesRibomicRibomic Usa IncAju Pharm Co Ltd
Inactive CompaniesN/A
Active IndicationsMacular DegenerationAchondroplasia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A